NEW YORK (GenomeWeb News) – Cancer care firm N-of-One today announced a deal with Foundation Medicine to translate sequencing data into clinically relevant information.

Under the terms of the agreement, Foundation will identify potential biomarkers using its sequencing and analytic capabilities on patient tumor samples. N-of-One will then use its PrecisionWorks platform to translate data from Foundation to link molecular changes with current information about relevant target therapies and clinical trials that may be used to guide treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.